Do microRNAs control inflammatory mediator production by airway epithelial cells from patients with asthma and COPD? - miR in asthma and COPD

Academisch Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•Asthma: non-smoking, allergic, intermittent to mild persistent asthma (history of episodic wheeze and shortness of breath). FEV1 predicted > 70% and PC20 histamine between 0.25 to 8 mg/ml.
•COPD: middle-age onset of symptoms, cigarette consumption of at least 15 pack-years and a post-bronchodilator FEV1/VC ratio smaller than 0.7. Reversibility in FEV1 assessed after the apropriate abstaining of bronchodilators, and measured follwing high dose of beta2-agonist inhalation was below 11% of predicted.
•Healthy individuals: no lung pathology

•Exacerbation requiring oral steroids or antibiotics for 3 months before the study and no lower respiratory tract infection for 4 weeks before the study. Inhaled corticosteroids, antibiotics, theophylline, sodium cromoglycate, or antileukotrienes were not allowed 4 weeks before and during the study. Specific exclusion criteria: for COPD patients: allergy; for asthma patients: smoking

发起方